查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1760548

2025年骨髓恶性肿瘤检测全球市场报告

Hematologic Malignancies Testing Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年骨髓恶性肿瘤检测市场规模将快速成长。到 2029 年，该市场规模将成长至 59.4 亿美元，复合年增长率为 13.4%。预测期内的成长动力包括个人化癌症治疗需求的不断增长、次世代定序仪的广泛应用、新兴市场医疗支出的不断增长、精准倡议的不断扩大，以及专注于血液癌症治疗的临床试验数量的不断增加。预期的主要趋势包括分子检测技术的进步、自动化和高通量诊断平台的开发、骨髓恶性肿瘤领域的持续研究和创新、人工智慧在检测解释中的整合，以及血液癌症液态切片方法的突破。

预计未来几年癌症诊断数量的增加将推动骨髓恶性肿瘤检测市场的成长。癌症诊断包括透过各种医学测试和评估（包括影像检查、实验室测试和切片检查）来确定患者癌症的存在、类型和分期。癌症诊断数量的增加归因于筛检计划的普及和公众意识的提高，从而可以更早发现癌症。骨髓恶性肿瘤检测透过早期发现、准确分类和监测血液相关癌症来支持癌症诊断，最终指导标靶治疗决策并改善患者预后。例如，根据美国非营利组织美国癌症协会的数据，2024 年美国新诊断的癌症患者将超过 200 万，年成长 4%。因此，癌症诊断数量的增加正在推动骨髓恶性肿瘤检测市场的成长。

骨髓恶性肿瘤检测市场的主要企业正专注于快速分子分析等创新诊断方法，为医疗专业人员提供准确及时的诊断工具，从而改善血癌的早期发现、治疗计划和监测。快速分子分析是一种诊断技术，它分析患者的基因图谱以识别突变和变异，从而能够更快、更个人化地制定治疗决策。例如，2023 年 11 月，美国癌症中心罗斯威尔帕克综合癌症中心推出了 PanHeme，这是一款下一代基因序列测定工具，旨在更准确、更快速地诊断白血病、淋巴瘤和多发性骨髓瘤等血癌。该测试可在 72 小时内检测出数百个基因的突变，显着提高诊断的速度和准确性，并支持更个人化的治疗方案。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场 - 宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球骨髓恶性肿瘤检测PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 最终用途产业分析
  • 全球骨髓恶性肿瘤检测市场：成长率分析
  • 全球骨髓恶性肿瘤检测市场表现：规模与成长，2019-2024
  • 全球骨髓恶性肿瘤检测市场预测：规模与成长，2024-2029，2034
  • 全球骨髓恶性肿瘤检测总目标市场（TAM）

第六章市场区隔

  • 全球骨髓恶性肿瘤检测市场（依检测类型、表现及预测），2019-2024 年、2024-2029 年、2034 年
  • 全血球计数（CBC）
  • 流式细胞技术
  • 分子检测
  • 基因检测
  • 其他测试类型
  • 全球骨髓恶性肿瘤检测市场（依产品、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 套件
  • 服务
  • 全球骨髓恶性肿瘤检测市场（依技术、绩效与预测），2019-2024 年、2024-2029 年、2034 年
  • 聚合酵素链锁反应（PCR）
  • 次世代定序（NGS）
  • 免疫组织化学（IHC）
  • 细胞遗传学
  • 其他技术
  • 全球骨髓恶性肿瘤检测市场（依治疗适应症、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 白血病
  • 淋巴瘤
  • 多发性骨髓瘤
  • 骨髓增生性肿瘤
  • 其他治疗适应症
  • 全球骨髓恶性肿瘤检测市场（依最终用户、绩效及预测）2019-2024、2024-2029、2034
  • 医院
  • 诊断实验室
  • 学术研究所
  • 其他最终用户
  • 全球骨髓恶性肿瘤检测市场、全血球计数 (CBC) 细分、按类型、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 血红素检测
  • 血球容积比测量
  • 白血球计数
  • 红血球计数
  • 血小板计数
  • 平均红血球体积（MCV）
  • 平均红血球血红素 (MCH)
  • 全球骨髓恶性肿瘤检测市场，按流式细胞技术类型细分，表现和预测，2019-2024 年、2024-2029 年、2034 年
  • 免疫表型分析
  • 细胞週期分析
  • 细胞凋亡检测
  • 微量残存疾病（MRD）检测
  • DNA含量分析
  • 全球骨髓恶性肿瘤检测市场，依分子检测类型细分，表现及预测，2019-2024 年、2024-2029 年、2034 年
  • 聚合酵素链锁反应（PCR）
  • 次世代定序（NGS）
  • 逆转录PCR（RT-PCR）
  • 萤光原位杂合反应（FISH）
  • 微阵列分析
  • 全球骨髓恶性肿瘤检测市场，依基因检测类型细分，绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 种系突变检测
  • 体细胞突变检测
  • 细胞遗传学检测
  • 染色体异常检测
  • 单核苷酸多态性（SNP）分析
  • 全球骨髓恶性肿瘤检测市场，其他检测类型细分，按类型、性能和预测，2019-2024 年、2024-2029 年、2034 年
  • 骨髓切片检查
  • 免疫组织化学（IHC）
  • 酵素测定
  • 血清蛋白电泳（SPEP）
  • 影像检查

第七章 区域和国家分析

  • 全球骨髓恶性肿瘤检测市场各地区、绩效及预测（2019-2024、2024-2029、2034）
  • 全球骨髓恶性肿瘤检测市场（依国家/地区划分）、绩效及预测（2019-2024 年、2024-2029 年、2034 年）

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 骨髓恶性肿瘤检测市场：竞争格局
  • 骨髓恶性肿瘤检测市场：公司简介
    • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
    • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • Abbott Laboratories
  • Novartis Aktiengesellschaft
  • GlaxoSmithKline Public Limited Company
  • Eli Lilly and Company
  • Laboratory Corporation of America Holdings
  • Agilent Technologies Inc.
  • Sun Pharmaceutical Industries Limited
  • Illumina Inc.
  • Bio-Rad Laboratories Inc.
  • Cipla Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Invitae Corporation
  • Adaptive Biotechnologies Corporation
  • Invivoscribe Inc.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029年骨髓恶性肿瘤检测市场：提供新机会的国家
  • 2029年骨髓恶性肿瘤检测市场：细分市场带来新机会
  • 2029年骨髓恶性肿瘤检测市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r35425

Hematologic malignancies testing involves diagnostic and monitoring procedures aimed at detecting, classifying, and assessing cancers of the blood, bone marrow, and lymphatic system. This testing provides precise identification of the type and subtype of malignancy, helps determine prognosis, informs treatment strategies, and tracks treatment response or disease relapse.

The primary types of tests for hematologic malignancies include complete blood count (CBC), flow cytometry, molecular testing, genetic testing, and other methods. A complete blood count (CBC) measures various blood components such as red blood cells, white blood cells, hemoglobin, hematocrit, and platelets. Products in this area are classified as kits and services. Technologies employed include polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), cytogenetics, among others. These tests address therapeutic indications like leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and more. They are utilized by a range of end-users including hospitals, diagnostic laboratories, academic institutions, research centers, and others.

The hematologic malignancies testing market research report is one of a series of new reports from The Business Research Company that provides hematologic malignancies testing market statistics, including the hematologic malignancies testing industry global market size, regional shares, competitors with the hematologic malignancies testing market share, detailed hematologic malignancies testing market segments, market trends, and opportunities, and any further data you may need to thrive in the hematologic malignancies testing industry. This hematologic malignancies testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hematologic malignancies testing market size has grown rapidly in recent years. It will grow from $3.16 billion in 2024 to $3.59 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth during the historic period can be attributed to an increasing incidence of blood cancers, heightened awareness of early cancer detection, expanded use of flow cytometry and molecular diagnostics, growth in hematology testing across hospitals and laboratories, and improved availability of reimbursement for cancer diagnostic procedures.

The hematologic malignancies testing market size is expected to see rapid growth in the next few years. It will grow to $5.94 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The projected growth in the forecast period is driven by increasing demand for personalized cancer treatments, wider adoption of next-generation sequencing, rising healthcare expenditures in emerging markets, expansion of precision oncology initiatives, and a growing number of clinical trials focused on blood cancer therapies. Key trends expected include advancements in molecular testing technologies, the development of automated and high-throughput diagnostic platforms, ongoing research and innovation in hematologic malignancies, integration of artificial intelligence in test interpretation, and breakthroughs in liquid biopsy methods for blood cancers.

The increasing number of cancer diagnoses is expected to drive the growth of the hematologic malignancies testing market in the coming years. Cancer diagnosis involves identifying the presence, type, and stage of cancer in a patient through various medical tests and evaluations such as imaging, laboratory tests, and biopsies. The rise in cancer diagnoses is attributed to improved access to screening programs and greater public awareness, leading to earlier detection. Hematologic malignancies testing supports cancer diagnosis by enabling early detection, accurate classification, and monitoring of blood-related cancers, which ultimately helps guide targeted treatment decisions and improves patient outcomes. For example, according to the American Cancer Society, a US-based nonprofit organization, over 2 million new cancer cases were diagnosed in the US in 2024, marking a 4% increase from previous years. Therefore, the rising number of cancer diagnoses is driving growth in the hematologic malignancies testing market.

Leading companies in the hematologic malignancies testing market are focusing on innovative diagnostic methods, such as rapid molecular profiling, to provide healthcare professionals with precise and timely diagnostic tools that improve early detection, treatment planning, and monitoring of blood cancers. Rapid molecular profiling is a diagnostic technique that analyzes a patient's genetic profile to identify mutations and variations, allowing for faster and more personalized treatment decisions. For instance, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based cancer center, launched PanHeme, a next-generation gene sequencing tool designed to diagnose hematologic cancers like leukemia, lymphoma, and multiple myeloma with greater accuracy and speed. This test detects mutations in hundreds of genes within 72 hours, significantly enhancing the speed and precision of diagnosis and supporting more personalized treatment plans.

In January 2025, Adaptive Biotechnologies Corporation, a US-based biotechnology firm specializing in hematologic malignancies testing, partnered with NeoGenomics Laboratories, Inc. to expand personalized disease monitoring for blood cancer patients. Through this collaboration, Adaptive Biotechnologies and NeoGenomics aim to broaden access to precise minimal residual disease monitoring in blood cancers by incorporating the clonoSEQ test into NeoGenomics' diagnostic services, thereby improving treatment decisions and disease tracking. NeoGenomics Laboratories Inc. is a US-based public, high-complexity clinical laboratory specializing in cancer genetics diagnostic testing.

Major players in the hematologic malignancies testing market are Johnson & Johnson Private Limited, F. Hoffmann-La Roche Aktiengesellschaft, Merck & Co. Inc., Bayer Aktiengesellschaft, AstraZeneca PLC, Abbott Laboratories, Novartis Aktiengesellschaft, GlaxoSmithKline Public Limited Company, Eli Lilly and Company, Laboratory Corporation of America Holdings, Agilent Technologies Inc., Sun Pharmaceutical Industries Limited, Illumina Inc., Bio-Rad Laboratories Inc., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Invitae Corporation, Adaptive Biotechnologies Corporation, Invivoscribe Inc.

North America was the largest region in the hematologic malignancies testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hematologic malignancies testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hematologic malignancies testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hematologic malignancies testing market consists of revenues earned by entities by providing biopsy testing, cytogenetic testing, and molecular testing (PCR, NGS). The market value includes the value of related goods sold by the service provider or included within the service offering. The hematologic malignancies testing market also includes sales of hematology analyzers, and bone marrow biopsy kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hematologic Malignancies Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hematologic malignancies testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hematologic malignancies testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hematologic malignancies testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Test Type: Complete Blood Count (CBC); Flow Cytometry; Molecular Testing; Genetic Testing; Others Test Type
  • 2) By Product: Kits; Services
  • 3) By Technology: Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Immunohisto Chemistry (IHC); Cytogenetics; Others Technology
  • 4) By Therapeutic Indication: Leukemia; Lymphoma; Multiple Myeloma; Myeloproliferative Neoplasms; Others Therapeutic Indication
  • 5) By End User: Hospitals; Diagnostic Labs; Academic and Research Institutions; Others End Users
  • Subsegments:
  • 1) By Complete Blood Count (CBC): Hemoglobin Testing; Hematocrit Measurement; White Blood Cell Count; Red Blood Cell Count; Platelet Count; Mean Corpuscular Volume (MCV); Mean Corpuscular Hemoglobin (MCH)
  • 2) By Flow Cytometry: Immunophenotyping; Cell Cycle Analysis; Apoptosis Detection; Minimal Residual Disease (MRD) Testing; DNA Content Analysis
  • 3) By Molecular Testing: Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Reverse Transcriptase-PCR (RT-PCR); Fluorescence In Situ Hybridization (FISH); Microarray Analysis
  • 4) By Genetic Testing: Germline Mutation Testing; Somatic Mutation Testing; Cytogenetic Testing; Chromosomal Aberration Detection; Single Nucleotide Polymorphism (SNP) Analysis
  • 5) By Others Test Type: Bone Marrow Biopsy; Immunohistochemistry (IHC); Enzyme Assays; Serum Protein Electrophoresis (SPEP); Imaging Tests
  • Companies Mentioned: Johnson & Johnson Private Limited; F. Hoffmann-La Roche Aktiengesellschaft; Merck & Co. Inc.; Bayer Aktiengesellschaft; AstraZeneca PLC
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hematologic Malignancies Testing Market Characteristics

3. Hematologic Malignancies Testing Market Trends And Strategies

4. Hematologic Malignancies Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Hematologic Malignancies Testing Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Hematologic Malignancies Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Hematologic Malignancies Testing Market Growth Rate Analysis
  • 5.4. Global Hematologic Malignancies Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Hematologic Malignancies Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Hematologic Malignancies Testing Total Addressable Market (TAM)

6. Hematologic Malignancies Testing Market Segmentation

  • 6.1. Global Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Complete Blood Count (CBC)
  • Flow Cytometry
  • Molecular Testing
  • Genetic Testing
  • Others Test Type
  • 6.2. Global Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Kits
  • Services
  • 6.3. Global Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohisto Chemistry (IHC)
  • Cytogenetics
  • Others Technology
  • 6.4. Global Hematologic Malignancies Testing Market, Segmentation By Therapeutic Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • Others Therapeutic Indication
  • 6.5. Global Hematologic Malignancies Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Diagnostic Labs
  • Academic And Research Institutions
  • Others End Users
  • 6.6. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Complete Blood Count (CBC), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hemoglobin Testing
  • Hematocrit Measurement
  • White Blood Cell Count
  • Red Blood Cell Count
  • Platelet Count
  • Mean Corpuscular Volume (MCV)
  • Mean Corpuscular Hemoglobin (MCH)
  • 6.7. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Flow Cytometry, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immunophenotyping
  • Cell Cycle Analysis
  • Apoptosis Detection
  • Minimal Residual Disease (MRD) Testing
  • DNA Content Analysis
  • 6.8. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Molecular Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Reverse Transcriptase-PCR (RT-PCR)
  • Fluorescence In Situ Hybridization (FISH)
  • Microarray Analysis
  • 6.9. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Genetic Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Germline Mutation Testing
  • Somatic Mutation Testing
  • Cytogenetic Testing
  • Chromosomal Aberration Detection
  • Single Nucleotide Polymorphism (SNP) Analysis
  • 6.10. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Others Test Type, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Bone Marrow Biopsy
  • Immunohistochemistry (IHC)
  • Enzyme Assays
  • Serum Protein Electrophoresis (SPEP)
  • Imaging Tests

7. Hematologic Malignancies Testing Market Regional And Country Analysis

  • 7.1. Global Hematologic Malignancies Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Hematologic Malignancies Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hematologic Malignancies Testing Market

  • 8.1. Asia-Pacific Hematologic Malignancies Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hematologic Malignancies Testing Market

  • 9.1. China Hematologic Malignancies Testing Market Overview
  • 9.2. China Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hematologic Malignancies Testing Market

  • 10.1. India Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hematologic Malignancies Testing Market

  • 11.1. Japan Hematologic Malignancies Testing Market Overview
  • 11.2. Japan Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hematologic Malignancies Testing Market

  • 12.1. Australia Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hematologic Malignancies Testing Market

  • 13.1. Indonesia Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hematologic Malignancies Testing Market

  • 14.1. South Korea Hematologic Malignancies Testing Market Overview
  • 14.2. South Korea Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hematologic Malignancies Testing Market

  • 15.1. Western Europe Hematologic Malignancies Testing Market Overview
  • 15.2. Western Europe Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hematologic Malignancies Testing Market

  • 16.1. UK Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hematologic Malignancies Testing Market

  • 17.1. Germany Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hematologic Malignancies Testing Market

  • 18.1. France Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hematologic Malignancies Testing Market

  • 19.1. Italy Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hematologic Malignancies Testing Market

  • 20.1. Spain Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hematologic Malignancies Testing Market

  • 21.1. Eastern Europe Hematologic Malignancies Testing Market Overview
  • 21.2. Eastern Europe Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hematologic Malignancies Testing Market

  • 22.1. Russia Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hematologic Malignancies Testing Market

  • 23.1. North America Hematologic Malignancies Testing Market Overview
  • 23.2. North America Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hematologic Malignancies Testing Market

  • 24.1. USA Hematologic Malignancies Testing Market Overview
  • 24.2. USA Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hematologic Malignancies Testing Market

  • 25.1. Canada Hematologic Malignancies Testing Market Overview
  • 25.2. Canada Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hematologic Malignancies Testing Market

  • 26.1. South America Hematologic Malignancies Testing Market Overview
  • 26.2. South America Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hematologic Malignancies Testing Market

  • 27.1. Brazil Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hematologic Malignancies Testing Market

  • 28.1. Middle East Hematologic Malignancies Testing Market Overview
  • 28.2. Middle East Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hematologic Malignancies Testing Market

  • 29.1. Africa Hematologic Malignancies Testing Market Overview
  • 29.2. Africa Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hematologic Malignancies Testing Market Competitive Landscape And Company Profiles

  • 30.1. Hematologic Malignancies Testing Market Competitive Landscape
  • 30.2. Hematologic Malignancies Testing Market Company Profiles
    • 30.2.1. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Hematologic Malignancies Testing Market Other Major And Innovative Companies

  • 31.1. Abbott Laboratories
  • 31.2. Novartis Aktiengesellschaft
  • 31.3. GlaxoSmithKline Public Limited Company
  • 31.4. Eli Lilly and Company
  • 31.5. Laboratory Corporation of America Holdings
  • 31.6. Agilent Technologies Inc.
  • 31.7. Sun Pharmaceutical Industries Limited
  • 31.8. Illumina Inc.
  • 31.9. Bio-Rad Laboratories Inc.
  • 31.10. Cipla Limited
  • 31.11. Hikma Pharmaceuticals PLC
  • 31.12. Lupin Limited
  • 31.13. Invitae Corporation
  • 31.14. Adaptive Biotechnologies Corporation
  • 31.15. Invivoscribe Inc.

32. Global Hematologic Malignancies Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hematologic Malignancies Testing Market

34. Recent Developments In The Hematologic Malignancies Testing Market

35. Hematologic Malignancies Testing Market High Potential Countries, Segments and Strategies

  • 35.1 Hematologic Malignancies Testing Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Hematologic Malignancies Testing Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Hematologic Malignancies Testing Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer